MITF and melanoma: Taken together, these data indicate osteoblast‐derived RANKL alters the balance of death and proliferation that occurs when melanoma cells are treated with BRAF inhibitor to decrease apoptosis and increase cell‐cycle entry via upregulation of MITF.